Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) to Treat Chemotherapy-induced Neutropenia

“Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations and with a primary focus in Hematology and Oncology, today announced that the key phase 2 trial of its long-acting granulocyte stimulating factor analog developed using LAPSCOVERY technology (SPI-2012) has completed its Phase 2 study enrollment; this positions Spectrum for Phase 3 decision making before year end.”

Editor’s note: Neutropenia is a potentially life-threatening side effect of chemotherapy. This clinical trial is testing whether a treatment called LAPSCOVERY is effective against neutropenia.